Teva Pharmaceutical to Replace CEO Kare Schultz - WSJ
Teva Agrees to Purchase Rimsa in $2.3 Billion Deal
Teva: Now What? | Barron's
Teva makes $40B offer for Mylan
Teva looks to sell generics in China through joint venture with Guangzhou Pharma: Bloomberg | Fierce Pharma
The Difficulties of Cloning a CEO - Bloomberg
US states sue Teva for price-fixing in 'multi-billion dollar fraud' | The Times of Israel
Teva Is Facing Adderall Supply Disruptions as Demand for ADHD Drug Soars - Bloomberg
Teva Offers Drugs Valued at $23 Billion to End Opioid Suits - Bloomberg
Teva halts output at U.S. drug plant after FDA flags concerns | Reuters
Teva Analysts Say Migraine Drug Approval Gives Needed Relief - Bloomberg
Teva Is 'on the Way' to Leaving Opioid Litigation Behind, CEO Says | Barron's
Teva CEO Kare Schultz Says Drugmaker Will Fight US Price-Fixing Charges - Bloomberg
Teva flags supply constraints to ADHD drug Adderall as demand rises (NYSE: TEVA) | Seeking Alpha
Teva to Sell Record $5 Billion of Sustainability-Linked Bonds - Bloomberg
Future Teva CEO Seeks to 'Formulate Clear Strategy' - YouTube
Teva shares jump in Tel Aviv after report of up to 10,000 job cuts | The Times of Israel
Teva CEO Resigns; Dividend Cut Should Be Next - Bloomberg
Teva's Budding Blockbuster Drugs Lend Respite From Legal Concerns - Bloomberg
Teva to Sell Record $5 Billion of Sustainability-Linked Bonds - Bloomberg
Teva Agrees to Settle Opioid Lawsuits for as Much as $4.25 Billion - WSJ
Teva Sees Adderall Supply Delays Continuing for 2-3 Months (1)
Teva Pharmaceuticals to pay New York $523 million to settle claims from its role in opioids crisis - ABC News
Teva, Units Held Liable for Fueling N.Y. Opioid Crisis - Bloomberg
Teva Plunges as U.S. Sales Drop Amid Generic Price Erosion - Bloomberg
Justice Dept reportedly may file charges in its generic-drug probe by year-end
